Compare abrdn Income Credit Strategies Fund (ACP) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs BioNTech SE - ADR — how do they compare? abrdn Income Credit Strategies Fund trades at $5.15 (market cap $641.16M), while BioNTech SE - ADR trades at $92.97 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 36.4× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 18.2% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| ACP | BNTX | |
|---|---|---|
Market Cap | $641.16M | $23.31B |
Sector | Financials | Health |
52-Week High | $5.98 | $119.34 |
52-Week Low | $5.01 | $83.89 |
Dividend Yield | 18.2% | — |
Enterprise Value | — | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.14, up 1.18% today, with a neutral technical signal and bearish moving averages. The stock shows strong profitability with a net income margin of 95.31% and a low P/E of 7.74, though revenue declined to $42.46M in 2025 from $79M in 2024. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns.
The outlook is mixed: attractive valuation and high dividends offer income appeal, but revenue volatility and high leverage pose risks. Analyst sentiment is cautious due to unsustainable distribution rates and tight credit spreads, requiring careful monitoring of earnings and credit conditions for future performance.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
